US Regulators Tighten Oversight on AI in Mental Health Care

Regulators in the US are taking a cautious approach to generative AI in mental health care. The FDA now applies a risk-based framework to oversee these tools. Meanwhile, courts and lawmakers are setting up early safeguards against potential harms linked to technology and mental well-being. AI tools for mental health are rapidly entering the market. These systems assist therapists and psychologists by streamlining tasks, and they are being tested and regulated at speed. The technology offers more than just chatbots—applications include personal sensing and natural language processing.

A global shortage of mental health professionals adds urgency to the issue. On average, there are only 13 professionals per 100,000 people, with severe gaps in low- and middle-income countries. Over a billion individuals worldwide live with conditions like anxiety or depression. AI could help by reducing costs and providing 24-hour support.

Some US states, including Vermont, have already banned certain AI uses in mental health services. This has created uncertainty for tech firms. To build trust, many companies are now consulting mental health experts to develop evidence-based products. Public discussions about the psychosocial impact of these technologies are also growing. The FDA’s risk-based strategy aims to balance innovation with safety. State-level restrictions and market pressures are pushing companies to adopt responsible practices. These steps could shape how AI is integrated into mental health care moving forward.